Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences Inc. demonstrates a positive financial outlook due to the robust performance of its lead product, Ingrezza, which is expected to grow at a double-digit rate and potentially reach approximately $3 billion in sales by 2028. Additionally, the promising pipeline, which includes two ongoing Phase 3 programs and expectations for new drug approvals every two years, strengthens the long-term growth narrative for the company. Furthermore, the demand for its recently launched drug, Crenessity, is significant, particularly in pediatric and female adult markets, with anticipated revenue nearly doubling to $632 million in fiscal year 2026.

Neurocrine Biosciences, Inc. reported a non-GAAP EPS of $1.88 for 4Q25, significantly missing consensus estimates, which were $2.31 and $2.20, suggesting potential struggles in operational performance. The company is adjusting its FY26 revenue estimate for Ingrezza to $2,729 million, reflecting a decline in net pricing by approximately 5%, amidst concerns over slowing growth due to market competition and limited patient compliance. Additionally, higher than anticipated R&D expenses, primarily related to ongoing Phase 3 studies, have raised operational costs, contributing to a downward adjustment in the company's financial projections.